Show simple item record

dc.contributor.authorEngerud, Hilde Renateen_US
dc.contributor.authorHope, Kirsten Øvergaarden_US
dc.contributor.authorBerg, Hege Fredriksenen_US
dc.contributor.authorFasmer, Kristine Eldeviken_US
dc.contributor.authorTangen, Ingvild Løbergen_US
dc.contributor.authorHaldorsen, Ingfrid S.en_US
dc.contributor.authorTrovik, Joneen_US
dc.contributor.authorKrakstad, Camillaen_US
dc.PublishedEngerud HRH, Hope KØ, Berg HF, Fasmer KE, Tangen IL, Haldorsen IS, Trovik J, Krakstad C. Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer. PLOS ONE. 2019;14:e0210585eng
dc.description.abstractObjective: Better biomarkers are needed in order to identify patients with endometrial carcinoma at risk of recurrence and who may profit from a more aggressive treatment regimen. Our objective was to explore the applicability of plasma growth differentiation factor 15 (GDF-15) as a marker for recurrent disease, as well as a marker for poor prognosis and lymph node metastases. Methods: EDTA-blood samples were obtained from 235 patients with endometrial cancer before primary surgery. For 36 of these patients, matching blood samples were collected at time of recurrence. Blood samples were also collected from 78 patients with endometrial hyperplasia. Plasma GDF-15 was measured by an enzyme-linked immunosorbent assay (ELISA). Preoperative pelvic MRI scans for 141 patients were investigated in parallel for imaging variables. Results: Preoperative plasma level of GDF-15 was significantly higher for patients who experienced recurrence (1780 ng/L; 95% CI; 518–9475 ng/L) than for patients who did not develop recurrent disease (1236 ng/L; 95% CI; 307–7030 ng/L) (p<0.001). Plasma levels of GDF-15 at recurrence (2818 ng/L, 95% CI 2088–3548 ng/L) were significantly higher than plasma levels of GDF-15 measured at time of primary diagnosis (1857 ng/L, 95% CI; 1317–2398 ng/L) (p = 0.001). High plasma level GDF-15 independently predicts recurrent disease (OR = 3.14; 95% CI 2.10–4.76) and lymph node metastases (OR = 2.64; 95% CI 1.52–4.61). Patients with high plasma level of GDF-15 had significantly larger tumor volume (p = 0.008). Conclusion: Elevated plasma level of GDF-15 is associated with aggressive disease and lymph node metastasis in endometrial carcinoma. GDF-15 may be helpful in indicating recurrent disease.en_US
dc.rightsAttribution CC BYeng
dc.titlePlasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial canceren_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2019 The Author(s)
dc.source.journalPLoS ONE
dc.relation.projectKreftforeningen: 190202
dc.relation.projectNorges forskningsråd: 273280

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution CC BY
Except where otherwise noted, this item's license is described as Attribution CC BY